Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

Also called NCT04942834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 320 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04942834
Other papers using this trial's data
  • Cryoballoon ablation vs. antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicentre randomized CEPAF trial Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026-09-02 DOI, PubMed 42677894, PMC13582022 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04942834. Randomized; no masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2025-08-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
Acronym
Cryo-InitialAF
Condition
Atrial Fibrillation, Persistent
Condition
Arrhythmias, Cardiac
Intervention (Drug)
Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone
Intervention (Device)
cryoballoon ablation
Lead sponsor
Ruijin Hospital (class: other)

Record details

Record id
cardio:ct-nct04942834
Content hash
d492f65ac34a636a8f272cc13c5c98b1959bcb4cabc4370337eacfd75e0f405c